RBRXF — Rhino Biotech Income Statement
0.000.00%
Last trade - 00:00Consumer DefensivesHighly SpeculativeMicro Cap
Annual income statement for Rhino Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 0.024 | 0.023 | 0.014 | 0.02 | 0.021 |
| Operating Profit | -0.024 | -0.023 | -0.014 | -0.02 | -0.021 |
| Net Income Before Taxes | -0.024 | -0.023 | -0.014 | -0.02 | -0.021 |
| Net Income After Taxes | -0.024 | -0.023 | -0.014 | -0.02 | -0.021 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.024 | -0.023 | -0.014 | -0.02 | -0.021 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.024 | -0.023 | -0.014 | -0.02 | -0.021 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0.001 | -0 | -0.001 | -0.001 |